Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 6.67
+0.06 (0.91%)
Jun 9, 2026, 3:00 PM CST
SHA:603567 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 481.09 | 768.47 | 2,677 | 3,084 | 4,199 | 4,120 |
Other Revenue | 28.63 | 28.86 | 26.93 | 54.11 | 14.68 | 6.5 |
| 509.72 | 797.34 | 2,704 | 3,138 | 4,214 | 4,127 | |
Revenue Growth (YoY) | -75.21% | -70.51% | -13.84% | -25.53% | 2.12% | 21.24% |
Cost of Revenue | 1,253 | 1,191 | 1,334 | 1,846 | 3,539 | 2,829 |
Gross Profit | -743.78 | -393.5 | 1,370 | 1,292 | 675.25 | 1,298 |
Selling, General & Admin | 314.4 | 359.68 | 575.22 | 979.01 | 915.17 | 952.16 |
Research & Development | 51.65 | 46.35 | 37.99 | 80.22 | 70.95 | 55.23 |
Other Operating Expenses | 23.92 | 23.99 | 36.03 | 43.79 | -64.36 | -24.14 |
Operating Expenses | 689.7 | 729.74 | 767.06 | 1,107 | 891.96 | 1,028 |
Operating Income | -1,433 | -1,123 | 602.9 | 185.52 | -216.71 | 270.38 |
Interest Expense | -139 | -139 | -137.09 | -135.41 | -138.68 | -144.79 |
Interest & Investment Income | 37.74 | 37.74 | 22.69 | 471.68 | 38.06 | 251.32 |
Currency Exchange Gain (Loss) | - | - | - | - | -0 | -0 |
Other Non Operating Income (Expenses) | -400.45 | -378.29 | 9.22 | -88.59 | 26.83 | -22.32 |
EBT Excluding Unusual Items | -1,931 | -1,603 | 497.73 | 433.2 | -290.5 | 354.6 |
Impairment of Goodwill | - | - | - | -2.4 | -1.28 | - |
Gain (Loss) on Sale of Investments | -11.92 | -11.95 | -9.69 | 0.6 | -1.75 | -0.15 |
Gain (Loss) on Sale of Assets | -1.7 | -0.85 | -2.31 | -0.26 | 39.33 | -1.11 |
Asset Writedown | 1.41 | -14.48 | - | -1.51 | - | -0.09 |
Other Unusual Items | 2.67 | 2.67 | 37.75 | 48.72 | 552.68 | 101.49 |
Pretax Income | -1,941 | -1,627 | 523.47 | 478.35 | 298.48 | 454.75 |
Income Tax Expense | -315.83 | -257.47 | 87.08 | 10.76 | 107.55 | 121.99 |
Earnings From Continuing Operations | -1,625 | -1,370 | 436.39 | 467.59 | 190.93 | 332.76 |
Minority Interest in Earnings | 3.11 | 3.4 | 1.82 | 5.15 | -5.49 | -0.66 |
Net Income | -1,622 | -1,367 | 438.22 | 472.74 | 185.44 | 332.1 |
Net Income to Common | -1,622 | -1,367 | 438.22 | 472.74 | 185.44 | 332.1 |
Net Income Growth | - | - | -7.30% | 154.93% | -44.16% | -23.88% |
Shares Outstanding (Basic) | 940 | 940 | 940 | 939 | 941 | 865 |
Shares Outstanding (Diluted) | 940 | 940 | 940 | 940 | 941 | 865 |
Shares Change (YoY) | -0.05% | -0.01% | -0.01% | -0.14% | 8.87% | 1.82% |
EPS (Basic) | -1.73 | -1.45 | 0.47 | 0.50 | 0.20 | 0.38 |
EPS (Diluted) | -1.73 | -1.45 | 0.47 | 0.50 | 0.20 | 0.38 |
EPS Growth | - | - | -7.30% | 155.28% | -48.71% | -25.24% |
Free Cash Flow | 602 | 253.57 | -24.84 | -573.38 | -731.07 | -882.57 |
Free Cash Flow Per Share | 0.64 | 0.27 | -0.03 | -0.61 | -0.78 | -1.02 |
Dividend Per Share | - | - | 0.150 | 0.200 | 0.028 | 0.106 |
Dividend Growth | - | - | -25.00% | 614.29% | -73.58% | - |
Gross Margin | -145.92% | -49.35% | 50.67% | 41.18% | 16.02% | 31.45% |
Operating Margin | -281.23% | -140.88% | 22.30% | 5.91% | -5.14% | 6.55% |
Profit Margin | -318.17% | -171.39% | 16.21% | 15.06% | 4.40% | 8.05% |
Free Cash Flow Margin | 118.10% | 31.80% | -0.92% | -18.27% | -17.35% | -21.39% |
EBITDA | -1,260 | -956.37 | 742.12 | 364.32 | -59.75 | 405.93 |
EBITDA Margin | -247.13% | -119.95% | 27.45% | 11.61% | -1.42% | 9.84% |
D&A For EBITDA | 173.79 | 166.88 | 139.22 | 178.8 | 156.95 | 135.55 |
EBIT | -1,433 | -1,123 | 602.9 | 185.52 | -216.71 | 270.38 |
EBIT Margin | -281.23% | -140.88% | 22.30% | 5.91% | -5.14% | 6.55% |
Effective Tax Rate | - | - | 16.63% | 2.25% | 36.03% | 26.82% |
Revenue as Reported | 798.06 | 798.06 | 2,707 | 3,144 | 4,219 | 4,130 |
Advertising Expenses | - | 12.14 | 15.94 | 10.42 | 3.57 | 2.17 |